Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced the extension of a biomarker discovery collaboration with Syngenta, a leading global agrochemical company. Syngenta has added the Refiner MS module for LC-MS and GC-MS metabolomic raw data processing and analysis to their existing Genedata Expressionist® system. Refiner MS expands Expressionist to process and analyze metabolomic raw MS data separately and in conjunction with microarray data, dramatically improving efficiency and enhancing the biomarker discovery process at Syngenta.
Syngenta has been successfully using the Genedata Expressionist Refiner Array and Analyst modules to process and analyze microarray data since 2005. With the rapid expansion of metabolomics research and the associated data volumes generated, Syngenta now uses Refiner MS to integrate MS data in their biomarker discovery projects.
With Refiner MS Syngenta can process more rapidly and with full confidence in quality extremely large amounts of MS data directly from multiple hardware platforms via user defined, flexible workflows. Peaks selection is performed automatically in Refiner MS while statistical analysis and biological pathway mapping are done in the powerful analytical module Analyst.
“Syngenta’s decision to use the Genedata Expressionist system for our metabolomics research is based on the ability of Refiner MS to capture very large data sets directly from a wide range of instruments quickly and efficiently and to visualize and manipulate data from a wide variety of mass spectrometry experiment types such as GC-MS and data dependent LC-MS/MS experiments all in one computer platform,” said Dr. David Portwood, head of Metabolomics at Syngenta UK. “A further major benefit is that we can now integrate all the "omics" data types in one platform and can perform multivariate stats within the Analyst module avoiding time consuming exporting and importing of data between software packages and leading, we believe, to greater understanding and insights to the biological processes that are key to the future success of our business.”
“We are very pleased at the continuing development of our relationship with Syngenta, a long-term Genedata customer and a global leader in agrochemical research,” said Dr. Othmar Pfannes, CEO of Genedata. “The expanded use of Expressionist at Syngenta is an excellent showcase of how Genedata’s products are meeting specific needs today for faster and more effective scientific exploration in a variety of life science research processes.”
Syngenta is one of the world's leading companies with more than 24,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.